Acadia Pharma (ACAD) Commences Pimavanserin Phase 3 as Adjunctive Treatment for Schizophrenia
Tweet Send to a Friend
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced the initiation of ENHANCE-1, a Phase III study to evaluate pimavanserin for adjunctive treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
